Paper42016346
Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.
Wang W and 1 other. Int J Nanomedicine, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation. Papers, record 42016346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42016346
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Heart Failure | Major topic |
| Nanomedicine | Major topic |
| Humans | |
| Animals | |
| Drug Delivery Systems | |
| Regeneration | |
| Nanoparticles |
Source PubMed
References141
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33233847 | Mitochondria-Targeted Drug Delivery in Cardiovascular Disease: A Long Road to Nano-Cardio Medicine. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/33233847 | PubMed |
| 2 | 33071711 | Biodegradable nanofibrous temperature-responsive gelling microspheres for heart regeneration. | Adv Funct Mater | 2020 | https://conductscience.org/library/papers/33071711 | PubMed |
| 3 | 23889805 | Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. | EPMA J | 2013 | https://conductscience.org/library/papers/23889805 | PubMed |
| 4 | 35456592 | Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35456592 | PubMed |
| 5 | 39267789 | Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury. | Theranostics | 2024 | https://conductscience.org/library/papers/39267789 | PubMed |
| 6 | 29920798 | Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases. | Adv Mater | 2018 | https://conductscience.org/library/papers/29920798 | PubMed |
| 7 | 27679742 | Small mammalian animal models of heart disease. | Am J Cardiovasc Dis | 2016 | https://conductscience.org/library/papers/27679742 | PubMed |
| 8 | 39036340 | Biomedical applications of stimuli-responsive nanomaterials. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39036340 | PubMed |
| 9 | 31682098 | Lanthanide Metal-Organic Framework Nanoprobes for the In Vitro Detection of Cardiac Disease Markers. | ACS Appl Mater Interfaces | 2019 | https://conductscience.org/library/papers/31682098 | PubMed |
| 10 | 19465864 | Patient-, provider-, and system-level barriers to heart failure care. | J Cardiovasc Nurs | 2009 | https://conductscience.org/library/papers/19465864 | PubMed |
| 11 | 39218342 | Nanomedicine: A great boon for cardiac regenerative medicine. | Eur J Pharmacol | 2024 | https://conductscience.org/library/papers/39218342 | PubMed |
| 12 | 35507131 | Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials. | Drug Deliv Transl Res | 2022 | https://conductscience.org/library/papers/35507131 | PubMed |
| 13 | 41210329 | Nanoparticle-based drug delivery systems targeting inflammatory immune mechanisms in acute myocardial infarction: current advances and perspectives. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41210329 | PubMed |
| 14 | 38089921 | Progress and prospect of nanotechnology for cardiac fibrosis treatment. | Interdiscip Med | 2023 | https://conductscience.org/library/papers/38089921 | PubMed |
| 15 | 39220195 | Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39220195 | PubMed |
| 16 | 20417314 | Inorganic nanomedicine--part 2. | Nanomedicine | 2010 | https://conductscience.org/library/papers/20417314 | PubMed |
| 17 | 34622671 | Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice. | J Am Heart Assoc | 2021 | https://conductscience.org/library/papers/34622671 | PubMed |
| 18 | 41197833 | The application of nanomedicines in repairing damage in myocardial infarction. | J Control Release | 2025 | https://conductscience.org/library/papers/41197833 | PubMed |
| 19 | 9403633 | Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. | Circulation | 1997 | https://conductscience.org/library/papers/9403633 | PubMed |
| 20 | 39385310 | Exosomes in nanomedicine: a promising cell-free therapeutic intervention in burn wounds. | Stem Cell Res Ther | 2024 | https://conductscience.org/library/papers/39385310 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42016346
GET https://conductscience.org/api/papers/v1/42016346/references?page=2